Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

2024-511254-51-00 Protocol EyeD-010-003 Human pharmacology (Phase I) - First administration to humans Ended

Start 9 Feb 2023 · End 26 Jun 2025 · Status Ended · 2 EU/EEA countries · 6 sites · Protocol EyeD-010-003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 18
Countries 2
Sites 6

Glaucoma

Key facts

Sponsor
Eyed Pharma
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Eye Diseases [C11]
Trial duration
9 Feb 2023 → 26 Jun 2025
Decision date (initial)
2024-06-07
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511254-51-00
EudraCT number
2020-002354-24
ClinicalTrials.gov
NCT06321562

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Glaucoma

VersionLevelCodeTermSystem organ class
26.0 PT 10048867 Pseudophakia 10042613
20.0 LLT 10030856 Open-angle glaucoma 10015919

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Eyed Pharma

Sponsor organisation
Eyed Pharma
Address
Rue Louis Plescia 9
City
Seraing
Postcode
4102
Country
Belgium

Scientific contact point

Organisation
Eyed Pharma
Contact name
Regulatory

Public contact point

Organisation
Eyed Pharma
Contact name
Regulatory

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 2 1
Germany Ended 16 5
Rest of world 0

Investigational sites

Belgium

1 site · Ended
Centre hospitalier universitaire de Liege
Ophthalmology, Avenue De L'hopital 1, 4000, Liege

Germany

5 sites · Ended
Universitaetsklinikum Tuebingen AöR
Department für Augenheilkunde, Elfriede-Aulhorn-Strasse 7, Nordstadt, Tuebingen
Knappschaftsklinikum Saar GmbH
Augenklinik Sulzbach, An Der Klinik 10, 66280, Sulzbach
Internationale Innovative Ophthalmochirurgie GbR (I.I.O.)
Breyer Kaymak Klabe Augenchirurgie, Martin-Luther-Platz 22/26, Stadtmitte, Duesseldorf
Universitaetsklinikum Heidelberg AöR
Augenklinik, Im Neuenheimer Feld 400, Neuenheim, Heidelberg
Otto Von Guericke Universitaet Magdeburg
Klinik und Poliklinik für Augenheilkunde, Leipziger Strasse 44, Leipziger Str., Magdeburg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2023-02-09 2023-03-01 2024-08-05
Germany 2023-12-14 2025-02-26 2025-06-26

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-19 Germany Acceptable
2024-05-07
2024-05-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-07 Germany Acceptable
2024-05-07
2024-08-07
3 SUBSTANTIAL MODIFICATION SM-1 2024-10-22 Germany Acceptable
2024-12-12
2024-12-16